Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)

Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy

(2014) Andreas S. Beutler et al.   ANNALS OF NEUROLOGY

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy

(2014) Daniel L. Hertz et al.   BREAST CANCER RESEARCH AND TREATMENT

Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel

(2014) J. E. Abraham et al.   CLINICAL CANCER RESEARCH

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

(2014) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel

(2013) D. L. Hertz et al.   ANNALS OF ONCOLOGY

Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy

(2013) Luis J Leandro-García et al.   JOURNAL OF MEDICAL GENETICS

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel

(2012) Daniel L. Hertz et al.   BREAST CANCER RESEARCH AND TREATMENT

Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy

(2012) Brandi N. Reeves et al.   CANCER

A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101

(2012) R. M. Baldwin et al.   CLINICAL CANCER RESEARCH

Detecting Rare Variant Effects Using Extreme Phenotype Sampling in Sequencing Association Studies

(2012) Ian J. Barnett et al.   GENETIC EPIDEMIOLOGY

Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study

(2012) Inés Llaudó et al.   TRANSPLANT INTERNATIONAL

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer

(2011) Troels K. Bergmann et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Using extreme phenotype sampling to identify the rare causal variants of quantitative traits in association studies

(2011) Dalin Li et al.   GENETIC EPIDEMIOLOGY

Eph receptors and ephrins in neuron-astrocyte communication at synapses

(2011) Keith K. Murai et al.   GLIA

Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1

(2011) Charles L. Loprinzi et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients

(2010) Roberta Rizzo et al.   BREAST CANCER RESEARCH AND TREATMENT

Chemotherapy-induced peripheral neurotoxicity

(2010) Guido Cavaletti et al.   Nature Reviews Neurology

Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer

(2010) T K Bergmann et al.   PHARMACOGENOMICS JOURNAL

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity

(2010) S Leskelä et al.   PHARMACOGENOMICS JOURNAL

Ephrin-A5 and EphA5 Interaction Induces Synaptogenesis during Early Hippocampal Development

(2010) Yukio Akaneya et al.   PLoS One

The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity

(2009) ANNA ÖFVERHOLM et al.   Oncology Letters

Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer

(2008) Henrik Gréen et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY